Sudeep Pharma Limited has submitted to the stock exchanges the copies of the newspaper advertisement published regarding its 37th Annual General Meeting (AGM). The notice was published in the Business Standard, Ahmedabad Edition, and Vadodara Samachar on Saturday, July 11, 2026. The submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The advertisement contains the Notice of the 37th AGM, along with information regarding E-Voting and Dividend Information. The company has stated that the above information is also available on its website at https://www.sudeeppharma.com/ . Dimple Mehta, the Company Secretary & Compliance Officer, signed the submission to the exchanges.

Key Dates for the 37th AGM

The notice outlines the specific schedule for the upcoming annual general meeting and the associated remote e-voting process.

The 37th AGM is scheduled to be held via Video Conferencing (VC) or other audio-visual means (OAVM). Shareholders holding shares as of the cut-off date are eligible to participate in the remote e-voting facility or vote via e-voting during the AGM.

Sudeep Pharma Limited has scheduled its 37th Annual General Meeting for Tuesday, August 4, 2026, at 11:00 a.m. via video conferencing. The meeting will seek shareholder approval for a final dividend of ₹1.50 per equity share for FY 2025-26 and the ratification of the Sudeep Pharma Employee Stock Option Scheme 2025. The record date for determining dividend eligibility is fixed as Thursday, July 23, 2026.

Financial Performance

The company's Annual Report for FY 2025-26 disclosed strong consolidated and standalone financial results. On a consolidated basis, revenue from operations reached ₹642.3 Crs, a 28% year-on-year increase from ₹501.99 Crs in FY 2024-25. Profit after tax grew 26% to ₹174.3 Crs with a PAT margin of 27.1%. EBITDA stood at ₹221.9 Crs with an EBITDA margin of 34.6%. Exports contributed 60% of consolidated revenue. The company maintained a conservative debt profile with total borrowings of ₹148.3 Crs and a debt-to-equity ratio of 0.17x.

On a standalone basis, the company reported a profit after tax of ₹10,758.07 lakh for FY 2025-26, compared to ₹9,574.77 lakh in the previous year. Standalone revenue from operations stood at ₹33,850.54 lakh.

Business Segment Performance

The Specialty Ingredients vertical was the fastest-growing segment, with revenue increasing 63% from ₹172 Crs to ₹280 Crs. The Pharmaceutical, Food & Nutrition core vertical contributed around ₹362 Crs, approximately 56% of revenue. For the Battery Materials business under Sudeep Advanced Materials, the company broke ground at Dahej in January 2026. Phase 1 capacity of 25,000 MT is planned for commissioning by April 2027, with around 700 MT of initial commercial orders already received.

AGM Agenda

The AGM will seek shareholder approval to ratify the 'Sudeep Pharma Employee Stock Option Scheme 2025', which covers options not exceeding 21,70,014. Shareholders will also vote on the re-appointment of Mr. Ajay Shrirang Kandelkar as a director and on a revision in his remuneration as Whole Time Director to ₹1,14,97,600 per annum effective from April 1, 2026. The agenda includes the appointment of Mr. Milin Mehta as a Non-Executive, Non-Independent Director. Additionally, the meeting will consider the appointment of Mr. Hemang Mehta as Secretarial Auditor for a term of five years and the ratification of remuneration for Cost Auditors M/s. Chetan Gandhi & Associates.